Nektar Therapeutics (NKTR) Gross Margin
- Gross margin · 12 months: Value (m); Formula and calculation Gross profit / revenue. Period ending 2026-06-30..
Gross margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Gross margin · 12 months | (m) | Gross profit / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Gross profit | (m) | Gross Profit |
| Revenue | 54.59M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | (m) | Cost of Goods and Services Sold |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Gross profit (USD) | Revenue (USD) | Cost of products and services (USD) | Gross margin |
|---|---|---|---|---|
| 2026-06-30 | (m) | $54.59M | (m) | (m) |
| 2026-03-31 | (m) | $55.63M | (m) | (m) |
| 2025-12-31 | (m) | $55.23M | $0.00 | (m) |
| 2025-09-30 | (m) | $62.60M | $7.98M | (m) |
| 2025-06-30 | (m) | $74.93M | $12.41M | (m) |
| 2025-03-31 | (m) | $87.25M | $22.15M | (m) |
| 2024-12-31 | (m) | $98.43M | $30.69M | (m) |
| 2024-09-30 | (m) | $93.14M | $29.99M | (m) |
| 2024-06-30 | (m) | $93.16M | $37.99M | (m) |
| 2024-03-31 | (m) | $90.17M | $35.24M | (m) |
| 2023-12-31 | (m) | $90.12M | $33.77M | (m) |
| 2023-09-30 | (m) | $88.26M | $32.72M | (m) |
| 2023-06-30 | (m) | $87.74M | $25.26M | (m) |
| 2023-03-31 | (m) | $88.83M | $23.38M | (m) |
| 2022-12-31 | (m) | $92.06M | $21.64M | (m) |
| 2022-09-30 | (m) | $95.04M | $21.57M | (m) |
| 2022-06-30 | (m) | $96.34M | $21.90M | (m) |
| 2022-03-31 | (m) | $103.08M | $24.46M | (m) |
| 2021-12-31 | (m) | $101.91M | $24.90M | (m) |
| 2021-09-30 | (m) | $100.36M | $23.06M | (m) |
| 2021-06-30 | (m) | $105.47M | $23.32M | (m) |
| 2021-03-31 | (m) | $125.99M | $21.42M | (m) |
| 2020-12-31 | (m) | $152.91M | $19.48M | (m) |
| 2020-09-30 | (m) | $163.31M | $21.14M | (m) |
| 2020-06-30 | (m) | $162.50M | $20.50M | (m) |
| 2020-03-31 | (m) | $136.97M | $19.75M | (m) |
| 2019-12-31 | (m) | $114.62M | $21.37M | (m) |
| 2019-09-30 | (m) | $120.58M | $22.85M | (m) |
| 2019-06-30 | (m) | $119.13M | $22.70M | (m) |
| 2019-03-31 | (m) | $1.18B | $23.21M | (m) |
| 2018-12-31 | (m) | $1.19B | $24.41M | (m) |
| 2018-09-30 | (m) | $1.25B | (m) | (m) |
| 2018-06-30 | (m) | $1.37B | (m) | (m) |
| 2018-03-31 | (m) | $321.00M | (m) | (m) |
| 2017-12-31 | (m) | $307.71M | (m) | (m) |
| 2017-09-30 | (m) | $249.70M | (m) | (m) |
| 2017-06-30 | (m) | $133.10M | (m) | (m) |
| 2017-03-31 | (m) | $131.28M | (m) | (m) |
| 2016-12-31 | (m) | $165.44M | (m) | (m) |
| 2016-09-30 | (m) | $167.35M | (m) | (m) |
| 2016-06-30 | (m) | $190.97M | (m) | (m) |
| 2016-03-31 | (m) | $180.87M | (m) | (m) |
| 2015-12-31 | (m) | $230.78M | (m) | (m) |
| 2015-09-30 | (m) | $210.97M | (m) | (m) |
| 2015-06-30 | (m) | $283.88M | (m) | (m) |
| 2015-03-31 | (m) | $289.74M | (m) | (m) |
| 2014-12-31 | (m) | $200.71M | (m) | (m) |
| 2014-09-30 | (m) | $212.30M | (m) | (m) |
| 2014-06-30 | (m) | $140.34M | (m) | (m) |
| 2014-03-31 | (m) | $145.69M | (m) | (m) |
| 2013-12-31 | (m) | $148.92M | (m) | (m) |
| 2013-09-30 | (m) | $138.92M | (m) | (m) |
| 2013-06-30 | (m) | $96.42M | (m) | (m) |
| 2013-03-31 | (m) | $86.25M | (m) | (m) |
| 2012-12-31 | (m) | $81.19M | (m) | (m) |
| 2012-09-30 | (m) | $75.83M | (m) | (m) |
| 2012-06-30 | (m) | $84.48M | (m) | (m) |
| 2012-03-31 | (m) | $78.13M | (m) | (m) |
| 2011-12-31 | $2.97M | $71.48M | (m) | 4.16% |
| 2011-09-30 | (m) | (m) | (m) | (m) |
| 2011-06-30 | (m) | (m) | (m) | (m) |
| 2011-03-31 | (m) | (m) | (m) | (m) |
| 2010-12-31 | $1.74M | $159.04M | (m) | 1.10% |
| 2010-09-30 | (m) | (m) | (m) | (m) |
| 2010-06-30 | (m) | (m) | (m) | (m) |
| 2010-03-31 | (m) | (m) | (m) | (m) |
| 2009-12-31 | (m) | $71.93M | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |